A Retrospective Cohort Study of Upfront Nilotinib in Chronic Myeloid Leukemia: A Single-Center Experience

Context Nilotinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia (CML). Aims We aim to evaluate the responses and safety of upfront Nilotinib therapy in Indian CML patients. Setting and Design We retrospectively reviewed the medical record...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Reema, Kapoor, Jyotsna, Ahmed, Rayaz, Mehta, Pallavi, Khushoo, Vishvdeep, Agrawal, Pragya, Bhurani, Dinesh, Agrawal, Narendra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Medical and Scientific Publishers Private Ltd 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719978/
https://www.ncbi.nlm.nih.gov/pubmed/34984204
http://dx.doi.org/10.1055/s-0041-1733301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719978/
https://www.ncbi.nlm.nih.gov/pubmed/34984204
http://dx.doi.org/10.1055/s-0041-1733301

Ejemplares similares